8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy

Rheumatoid Arthritis & Autoimmune Pharmacotherapy

Executive Summary: Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune inflammatory disease characterized by symmetric polyarthritis, progressive synovial pannus formation, cartilage destruction, and bone erosions. Under the 2021 American College of Rheumatology (ACR) Guidelines for the Treatment of Rheumatoid Arthritis, management is guided by a rigorous Treat-to-Target (T2T) strategy aiming for sustained clinical remission or low disease activity. Methotrexate remains the universal first-line anchor conventional synthetic DMARD (csDMARD). For patients with moderate-to-severe disease activity failing csDMARD monotherapy, combination therapy with Biologic DMARDs (bDMARDs) or Targeted Synthetic DMARDs (tsDMARDs / JAK inhibitors) is indicated. Ambulatory pharmacists must expertly manage pre-immunosuppression infectious screening (latent TB, Hepatitis B/C), navigate complex boxed warnings (thrombosis, malignancies, MACE), enforce vaccination rules, and ensure safe teratogenic washouts.

1. Pathophysiology, Diagnostic Biomarkers & Treat-to-Target (T2T) Strategy

Autoimmune Pathogenesis & Joint Anatomy

RA is driven by an autoimmune loss of self-tolerance in genetically susceptible individuals (HLA-DRB1 "shared epitope"). Autoreactive CD4+ T-helper cells (Th1, Th17) infiltrate the synovium, secreting pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1). These cytokines stimulate synovial fibroblasts and macrophages to proliferate into an invasive, hypervascularized tissue called a pannus. The pannus invades and degrades articular cartilage via matrix metalloproteinases (MMPs) and activates osteoclasts via the RANKL pathway, producing irreversible periarticular bone erosions.

                                  RHEUMATOID ARTHRITIS PANNUS CASCADE
                                  
     [ Genetic Predisposition (HLA-DRB1) + Environmental Trigger (Smoking / Periodontitis) ]
                                                  │
                                                  ▼
                     [ Citrullination of Endogenous Proteins (PAD Enzymes) ]
                                                  │
                                                  ▼
                     [ Generation of High-Affinity Anti-CCP & RF Autoantibodies ]
                                                  │
                                                  ▼
       [ Synovial Infiltration: Macrophages, T-Cells, B-Cells ──> TNF-α, IL-6, IL-1 Release ]
                                                  │
                                                  ▼
          [ Synovial Hyperplasia & Neovascularization ──> INVASIVE PANNUS FORMATION ]
                                                  │
                     ┌────────────────────────────┴────────────────────────────┐
                     ▼                                                         ▼
     [ Chondrocyte MMP Release ]                               [ Osteoclast RANKL Activation ]
     • Articular Cartilage Degradation                         • Subchondral Bone Erosions
     • Symmetric Joint Space Narrowing                         • Permanent Joint Deformity

Clinical Presentation & Diagnostic Biomarkers

• Clinical Presentation: Symmetrical, inflammatory polyarthritis primarily affecting small joints of the hands and feet: Metacarpophalangeal (MCP), Proximal Interphalangeal (PIP), Metatarsophalangeal (MTP), and wrists. Sparing of the Distal Interphalangeal (DIP) joints and thoracolumbar spine (which distinguishes RA from osteoarthritis).
• Morning Stiffness: Prominent inflammatory morning stiffness lasting > 30 to 60 minutes, improving with movement and activity.
• Diagnostic Serologies:
  • Rheumatoid Factor (RF): Autoantibody against IgG Fc portion. Sensitivity ~70–80%, but lower specificity (found in SLE, Sjögren's, chronic Hepatitis C, and healthy older adults).
  • Anti-Cyclic Citrullinated Peptide (Anti-CCP / ACPA): High sensitivity (~70–80%) and exceptional specificity (>95%). Anti-CCP positivity strongly correlates with aggressive, erosive disease and rapid radiographic progression.
  • Acute Phase Reactants: Elevated ESR and C-reactive protein (CRP) correlate with active systemic inflammation.

The Treat-to-Target (T2T) Implementation Algorithm

• Target Definition: Aim for Remission (or Low Disease Activity in long-standing disease) using validated composite instruments: CDAI (Clinical Disease Activity Index ≤2.8 for remission), SDAI (Simplified Disease Activity Index ≤3.3), or DAS28 (Disease Activity Score in 28 joints <2.6).
• Frequency of Assessment: Re-evaluate disease activity every 1 to 3 months during active disease.
• Adjustment Window: If no clinically meaningful improvement is observed by 3 months, or target is not achieved by 6 months, modify and intensify DMARD pharmacotherapy.
• Short-Term Glucocorticoid Bridging: Short-term systemic glucocorticoids (prednisone ≤ 10 mg daily) are conditionally recommended ONLY as a temporary "bridge" (< 3 months) while waiting for csDMARDs to achieve onset of action (6–12 weeks). Long-term maintenance steroids are strongly discouraged due to cumulative systemic toxicity (osteoporosis, infection, fractures, diabetes).

2. Conventional Synthetic DMARDs (csDMARDs)

Conventional synthetic DMARDs form the initial backbone of pharmacotherapy in all patients diagnosed with rheumatoid arthritis.

1. Methotrexate (MTX) — The Gold Standard Anchor csDMARD

• Dosing & Administration: 7.5 to 25 mg orally or subcutaneously ONCE WEEKLY (NEVER daily for RA). Starting dose is typically 15 mg once weekly, escalating rapidly by 2.5–5 mg every 2–4 weeks toward a target of 20 to 25 mg weekly as tolerated.
• Subcutaneous Administration: If oral MTX produces intolerable GI adverse effects or fails to achieve target disease activity at doses ≥15–20 mg weekly, switch directly to subcutaneous MTX (which provides superior, linear bioavailability and lower GI intolerance).
• Mandatory Folic Acid Co-Prescription: Prescribe Folic Acid 1 to 5 mg orally once daily (or 5 mg weekly the day after MTX). Folic acid supplementation significantly reduces MTX-induced adverse events: nausea, abdominal pain, oral aphthous stomatitis/ulcers, alopecia, macrocytic anemia, and transaminitis without diminishing antirheumatic efficacy.
• Contraindications: Pregnancy (teratogenic / embryocidal), breastfeeding, chronic liver disease or heavy alcohol consumption, severe renal impairment (eGFR < 30 mL/min), and baseline bone marrow dyscrasias.
• Adverse Effects & Monitoring:
  • Baseline Labs: CBC with differential, LFTs (AST, ALT, albumin), Serum Creatinine/eGFR, Hepatitis B/C serologies, pregnancy test, and baseline chest X-ray.
  • Routine Monitoring: CBC, LFTs, and SCr every 2–4 weeks for the first 3 months, then every 8–12 weeks.
  • Pulmonary Toxicity: Hypersensitivity pneumonitis (dry cough, dyspnea, fever); requires immediate MTX cessation and urgent evaluation.

2. Leflunomide (Arava)

• Mechanism: Selectively inhibits dihydroorotate dehydrogenase (DHODH), blocking de novo pyrimidine synthesis and arresting proliferating activated T-lymphocytes in the G1 phase.
• Dosing: 10 to 20 mg orally once daily. (The historical loading dose of 100 mg daily for 3 days is routinely omitted to avoid severe nausea and diarrhea).
• Pharmacokinetics & Teratogenicity: Its active metabolite, teriflunomide, undergoes extensive enterohepatic circulation with an elimination half-life of ~2 weeks, taking up to 2 years to clear spontaneously. Strictly contraindicated in pregnancy.
• Accelerated Cholestyramine Washout Protocol: If pregnancy is planned, or in cases of severe toxicity (hepatotoxicity, severe infection), administer Cholestyramine 8 g orally 3 times daily for 11 days (or activated charcoal 50 g QID for 11 days). Verify that plasma teriflunomide concentrations are < 0.02 mg/L on two separate blood draws at least 14 days apart prior to conception.
• Monitoring: LFTs, CBC, and blood pressure (causes new-onset or worsening hypertension).

3. Hydroxychloroquine (Plaquenil)

• Role in RA: Preferred csDMARD for mild disease activity, or as part of "triple therapy" (Methotrexate + Sulfasalazine + Hydroxychloroquine).
• Dosing & Toxicity Threshold: 200 to 400 mg orally once daily. Maximum daily dose must not exceed ≤ 5.0 mg/kg/day based on ACTUAL body weight to minimize retinal toxicity.
• Retinal Screening Guidelines (American Academy of Ophthalmology [AAO]): Baseline comprehensive ophthalmologic examination within 1 year of initiation (dilated fundus exam, automated visual field 10-2 testing, spectral-domain OCT), followed by annual screening starting after 5 years of use (or earlier if high risk: dose >5.0 mg/kg, eGFR <60 mL/min, concomitant tamoxifen use).
• Safety Profile: Lacks hepatic, renal, and myelosuppressive toxicity; safe in pregnancy and lactation.

4. Sulfasalazine (Azulfidine)

• Dosing: Start 500 mg orally daily to BID with food; titrate to 2 to 3 g/day in divided doses.
• Clinical Nuances: Cleaved by colonic bacteria into sulfapyridine and 5-aminosalicylic acid (5-ASA). Safe in pregnancy (requires concurrent folic acid 1–2 mg daily because sulfasalazine inhibits intestinal folate absorption). Contraindicated in patients with severe sulfa allergy or salicylate allergy. Causes benign orange-yellow discoloration of urine and skin.

3. Biologic DMARDs (bDMARDs) & Targeted Synthetic DMARDs (tsDMARDs)

Biologic & Targeted Synthetic DMARD Comparative Master Table

4. Pre-Biologic / Pre-JAK Screening & Immunization Protocols

Prior to initiating any biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD / JAK inhibitor), clinicians must systematically execute mandatory infectious disease screenings and verify vaccination records.

1. Latent Tuberculosis Infection (LTBI) Screening Protocol

• Mandatory Baseline Screening: Screen all patients for latent tuberculosis using an Interferon-Gamma Release Assay (IGRA) (e.g., QuantiFERON-TB Gold, T-Spot.TB) or a Tuberculin Skin Test (TST / PPD). IGRA is preferred in patients with prior BCG vaccination.
• Management of Positive Latent TB Screen:
  1. Obtain a baseline chest radiograph to rule out active pulmonary tuberculosis.
  2. Initiate targeted latent TB treatment (e.g., Rifampin 600 mg daily for 4 months, or Isoniazid 300 mg daily for 9 months, or once-weekly Isoniazid + Rifapentine for 3 months).
  3. The 1-Month Delay Rule: The patient must complete at least 1 full month (4 weeks) of anti-tuberculosis therapy before initiating the biologic DMARD or JAK inhibitor.

2. Viral Hepatitis Serology Screening

• Hepatitis B Virus (HBV): Test for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc total), and Hepatitis B surface antibody (anti-HBs).
  • If active HBV (HBsAg+) or resolved/occult HBV (anti-HBc+ without surface antibody), initiate prophylactic antiviral therapy (entecavir, tenofovir) in collaboration with hepatology prior to initiating immunosuppressive therapy (especially Rituximab or anti-TNF agents, which carry high risks of fulminant fatal HBV reactivation).
• Hepatitis C Virus (HCV): Test for HCV antibody. If positive, confirm with HCV RNA; treat with direct-acting antivirals (DAAs).

3. Immunization Timing Rules for Immunocompromised Patients

                                  VACCINATION RULES IN RA PHARMACOTHERAPY
                                  
    ┌───────────────────────────────────────────────┴───────────────────────────────────────────────┐
    ▼                                                                                               ▼
[ INACTIVATED / RECOMBINANT VACCINES ]                                          [ LIVE ATTENUATED VACCINES ]
• Safe before AND during therapy.                                               • MMR, Varicella, Yellow Fever, Live Flu.
• Annual Inactivated Influenza.                                                 • MUST be administered ≥ 4 WEEKS BEFORE
• Pneumococcal: PCV20 alone OR PCV15 followed by PPSV23.                          initiating bDMARDs or tsDMARDs.
• Recombinant Zoster (Shingrix): 2-dose series (0, 2-6m)                         • STRICTLY CONTRAINDICATED while
  STRONGLY RECOMMENDED for all adults ≥19 on immunosuppressive therapy.            actively receiving bDMARDs or JAKi.
• COVID-19, Tdap, Hepatitis B.                                                 • Risk of disseminated vaccine-strain infection.